ENSEM: ENSEM Raises $67 Million in A Round for Structure-Based Oncology Drugs

Boston's ENSEM Therapeutics closed a Series A2 financing that brings its total Series A to $67 million. Incubated by CBC group since 2021, ENSEM is a biotech focused on difficult-to-drug oncology targets, using its Kinetic EnsembleTM platform to develop small molecule precision medicines for oncology. ENSEM integrates computational and AI deep learning technology with experimental validation to identify novel binding pockets and accelerate structure-based drug design. The A2 round was led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui and CBC Group. More details.... Share this with colleagues: